Risk Factors That Help Inform Treatment Selection in Frontline EGFR-Mutated NSCLC

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, examine clinical and molecular risk factors that influence frontline treatment selection in EGFR-mutated non–small cell lung cancer. Vokes discusses the impact of CNS metastases, co-mutations, tumor burden, and patient performance status on therapeutic strategy. Devarakonda emphasizes individualized decision-making to balance efficacy, toxicity, and long-term sequencing considerations.